James M. Frates, Director at Sage Therapeutics, Inc. (SAGE), sold 7,500 shares at $134.81 ($1.0M) on 2019-01-23, disclosed to the SEC on 2019-01-24.
Open-market sale of $1.0M SAGE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |